Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So they had -3 MM free cash flow in Q2 and are predicting it will improve in Q3 but still ne negative according to IR?
" They are able to service the debt (part of the -3.3M FCF calculation) with a gross revenue of $31M/quarter."
Please provide more details how you got this I have an MBA and would like the numbers
Logic told me that if HSBC gave them 7 MM they were Ok but the share price decline to these level s has me very pessimistic. Could be tax selling.
OXBT could do another SRXS and open at $5 tomorrow
Hoping for the best but expecting the worst
The chart is horrible.
Monster News on OXBT AH could open at $5 tomorrow like STXS did after huge news
Good post.
who cares if he left?
CXM $1.03 + $.22 FDA approved drug
CXM could next STXS IMO, only 6 MM shares OS
No other biotech I know with an FDA approved product trades for less than $50 MM market cap.
Tons of other catalysts too, expanded distrbution of Exalgen, Insurance coverage, FDA application for improved Exalgen.
Don't get me wrong, its no blue chip, but in this biotech market, this could go much higher.
CXM $1.03 + $.22 6 MM Float FDA approved drug
CXM will be teh next STXS and go to $8 IMO.
No other biotech I know with an FDA approved product trades for less than $50 MM market cap, if CXM did it would be $8.
Tons of other catalysts too, expanded distrbution of Exalgen, Insurance coverage, FDA application for improved Exalgen.
CXM $1.03 + $.22 6 MM Float FDA approved drug
CXM will be teh next STXS and go to $8 IMO.
No other biotech I know with an FDA approved product trades for less than $50 MM market cap, if CXM did it would be $8.
Tons of other catalysts too, expanded distrbution of Exalgen, Insurance coverage, FDA application for improved Exalgen.
SCON $(1.66) may go to $3 short term
-Trades at cash value, no value given market to patents and technology
-$4 Target by Ladenburg
-Huge exposure at next weeks conference could be significant news
-Projects positive cash flow in 2014
-Historically traded at $100 MM market cap - that would give $8 value
-Very high beta, moves very quickly on news
ENG ($1.20) $20 MM asset sale after hours should run Tuesday
http://finance.yahoo.com/news/englobal-finalizes-sale-gulf-coast-213500355.html
This energy service stock offers a compelling valuation after this sale:
-$1.10 per share current assets and no debt
-Retains its most profitable segment with operations in Houston and Midwest
-Historically traded as high as $14 when it was profitable
-Small tightly held 23 MM float
-Some of the smartest hedge funds like Renaissance hold stakes
ENG ($1.20) $20 MM asset sale after hours should run Tuesday
http://finance.yahoo.com/news/englobal-finalizes-sale-gulf-coast-213500355.html
This energy service stock offers a compelling valuation after this sale:
-$1.10 per share current assets and no debt
-Retains its most profitable segment with operations in Houston and Midwest
-Historically traded as high as $14 when it was profitable
-Small tightly held 23 MM float
-Some of the smartest hedge funds like Renaissance hold stakes
ISIG $2.90 should be $5 IMO
ISIG has $20 MM cash, only 12 MM shares OS and EBITDA run rate going forward should be $4 - $5 MM.
I get a fair value at 10 x EBITDA of $5.
Forbes recently put out very positive article
I rode STXS from $2 to $8, IPCI is next. This is highest volume with no news in years.
Good luck I expect $2 short term.
INUV ($1.01) trades at 4 x EBITDA, 60% growth, Insider buying.A growth company like INUV trading at 4 x EBITDA won't last.
More insider buying today.
Could move to $3 in no time like ZHNE.
INUV ($1.01) trades at 4 x EBITDA, 60% growth, Insider buying.
A growth company like INUV trading at 4 x EBITDA won't last.
More insider buying today.
Couild easily move to $3 in no time like ZHNE did.
CEP big news after hours Cheapest oil and gas play out there trades at 3 x EBITDAhttp://finance.yahoo.com/news/constellation-energy-partners-initiates-business-211100353.html
MEET:NASDAQ ($1.73 +$.20)is a social media company with exploding mobile revenies and an international footprint.
MEET is in better shape than ever.
Just got $5 MM non dilutive financing, and mobile revenue is exploding. Will turn cash flow positive very soon.
The market loves fast growing social media companies with mobile business. GLUU was $6 last year and MEET has way better fundamentals.
Looking fcr $3 very soon.
MEET:NASDAQ ($1.73 +$.20)is an social media company with exploding mobile revenies and an international footprint.
MEET is on better shape than ever.
Just got $5 MM non dilutive financing, and mobile revenue is exploding. Will turn cash flow positive very soon.
The market loves fast growing social media companies with mobile business. GLUU was $6 last year and MEET has way better fundamentals.
Looking fcr $3 very soon.
ZHNE going to $1.50 very quickly. $1 per share current assets, no debt, hot sector, small float, profitable
You will not find a bigger no brainer IMO.
ZHNE going to $1.50 very quickly. $1 per share current assets, no debt, hot sector, small float, profitable
You will not find a bigger no brainer IMO.
CBMX exploding 1.2 MM float turning cash flow positive
2013 WILL BE A BREAKOUT YEAR FOR CBMX. THE CEO PREDICTS POSITIVE CASH FLOW "RELATIVELY QUICKLY" BASED ON THE FOLLOWING TRENDS:
- SALES FOR CBMX HIGH MARGIN PRENATAL TESTS ROSE 172% IN 2012.
-15% GROWTH RATE IN 2012 SHOULD ACCELERATE in 2013 as oncology stabilizes and PRENATAL REVENUE CONTINUES TO RAMP.
- CBMX has a current market cap of $4 million, which is a fraction of other companies in the Molecular diagnostics space. ROSG trades at a $40 MM market cap. If CBMX traded at same valuation it would be $30.
- CBMX has streamlined the organization and slashed costs to the bone.
- Tightly held 1.2 Million float.
- CBMX traded at $17 in 2012, and 2013 results will be far better.
In short, CBMX has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- 1.2 MM share float.
- $4 MM market cap.
- 170% growth rate in most profitable segment, prenatal tests.
- Growth will accelerate in 2013 and cash flow positive reached "relatively quickly" per CEO guidance.
- Traded at $17+ in 2012.
-Trading at 90% discount to peers.
CBMX CEO said breakeven coming quickly in CC
With a 1.2 MM float and 4 MM market cap CBMX is cheap.
From the CC:
SALES FOR CBMX HIGH MARGIN PRENATAL TESTS ROSE 172% IN 2012.
15% GROWTH RATE IN 2012 SHOULD ACCELERATE in 2013 as oncology stabilizes and PRENATAL REVENUE CONTINUES TO RAMP.
- CBMX has a current market cap of $4 million, which is a fraction of other companies in the Molecular diagnostics space. ROSG trades at a $40 MM market cap. If CBMX traded at same valuation it would be $30.
- CBMX has streamlined the organization and slashed costs to the bone.
- Tightly held 1.2 Million float.
- CBMX traded at $17 in 2012, and 2013 results will be far better.
In short, CBMX has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- 1.2 MM share float.
- $4 MM market cap.
- 170% growth rate in most profitable segment, prenatal tests.
- Growth will accelerate in 2013 and cash flow positive reached "relatively quickly" per CEO guidance.
- Traded at $17+ in 2012.
-Trading at 90% discount to peers
CBMX: 1.2 MM float, turning cash flow positive:
2013 WILL BE A BREAKOUT YEAR FOR CBMX. THE CEO PREDICTS POSITIVE CASH FLOW "RELATIVELY QUICKLY" BASED ON THE FOLLOWING TRENDS:
- SALES FOR CBMX HIGH MARGIN PRENATAL TESTS ROSE 172% IN 2012.
-15% GROWTH RATE IN 2012 SHOULD ACCELERATE in 2013 as oncology stabilizes and PRENATAL REVENUE CONTINUES TO RAMP.
- CBMX has a current market cap of $4 million, which is a fraction of other companies in the Molecular diagnostics space. ROSG trades at a $40 MM market cap. If CBMX traded at same valuation it would be $30.
- CBMX has streamlined the organization and slashed costs to the bone.
- Tightly held 1.2 Million float.
- CBMX traded at $17 in 2012, and 2013 results will be far better.
In short, CBMX has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- 1.2 MM share float.
- $4 MM market cap.
- 170% growth rate in most profitable segment, prenatal tests.
- Growth will accelerate in 2013 and cash flow positive reached "relatively quickly" per CEO guidance.
- Traded at $17+ in 2012.
-Trading at 90% discount to peers.
((( CBMX DD SUMMARY: $12 TARGET )))
2013 WILL BE A BREAKOUT YEAR FOR CBMX. THE CEO PREDICTS POSITIVE CASH FLOW "RELATIVELY QUICKLY" BASED ON THE FOLLOWING TRENDS:
- SALES FOR CBMX HIGH MARGIN PRENATAL TESTS ROSE 172% IN 2012.
-15% GROWTH RATE IN 2012 SHOULD ACCELERATE in 2013 as oncology stabilizes and PRENATAL REVENUE CONTINUES TO RAMP.
- CBMX has a current market cap of $4 million, which is a fraction of other companies in the Molecular diagnostics space. ROSG trades at a $40 MM market cap. If CBMX traded at same valuation it would be $30.
- CBMX has streamlined the organization and slashed costs to the bone.
- Tightly held 1.2 Million float.
- CBMX traded at $17 in 2012, and 2013 results will be far better.
In short, CBMX has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- 1.2 MM share float.
- $4 MM market cap.
- 170% growth rate in most profitable segment, prenatal tests.
- Growth will accelerate in 2013 and cash flow positive reached "relatively quickly" per CEO guidance.
- Traded at $17+ in 2012.
-Trading at 90% discount to peers.
FFEX is up signifcantly since Q2 earnings, but is still trading at a huge discount.
FFEX announced $.06 EPS in Q4 2009, AND IS PROJECTED TO EARN AT LEAST $.26 PER SHARE IN THE SECOND HALF OF 2012 BASED ON THE FOLLOWING GUIDANCE FROM THE CEO:
-The Company expects that quarterly results will continue to improve throughout the year.
-We are on track to restore the Company to profitability this year.
-FFEX trades at a P/S ratio of 0.07 compared to the Industry average of 0.62 If FFEX traded at even HALF the sector average it would be $5.
FFEX has slashed costs to the bone by investing in fuel efficient trucks. They are growing revenues and more importantly, MARGINS, by diversifying into bulk water transportation for the crude oil sector.
FFEX has a tightly held 11 Million float.
FFEX traded at $10 in 2007. The results projected for the second half of 2012 will surpass the 2007 results.
In short, FFEX has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- Profitable
- 11 MM share float
- $25 MM market cap
- $380 MM + revenues
- Will earn at least $.26 EPS in second hald of 2012 based on CEO guidance.
- Traded at $10+ in 2007
- Frequently mentioned as acquisition candidate because of heavy industry consolidion
- Diversification into water trucking business for oil sector substantially improving sales and margins and provides huge growth opportunity
CBMX $3.45 + $.28 1.0 MM float, new financing CEO said turning cash flow positive soon
.
Okay. And then 1 last question for Scott. Do you have a breakeven sales number that you're working with?
Scott R. Burell - Chief Financial Officer, Principal Accounting Officer, Treasurer and Secretary
Yes. We're not providing forward-looking estimates at this time other than just what we've talked about before, which is this strategy of focusing on the prenatal markets and on the CMAs, those are the highest reimbursed tests that we perform. They carry the best gross margin of any of our tests, and that's where all of the growth is coming right now. So we're excited about maximizing that opportunity and I think in the relative short term, turning around that breakeven point relatively quickly. But that's probably about as much as we can comment at this time.
CBMX $3.45 + $.28 1.0 MM float, CEO said turning cash flow positive soon
Okay. And then 1 last question for Scott. Do you have a breakeven sales number that you're working with?
Scott R. Burell - Chief Financial Officer, Principal Accounting Officer, Treasurer and Secretary
Yes. We're not providing forward-looking estimates at this time other than just what we've talked about before, which is this strategy of focusing on the prenatal markets and on the CMAs, those are the highest reimbursed tests that we perform. They carry the best gross margin of any of our tests, and that's where all of the growth is coming right now. So we're excited about maximizing that opportunity and I think in the relative short term, turning around that breakeven point relatively quickly. But that's probably about as much as we can comment at this time.
CBMX $3.45 + $.28 1.0 MM float, new financing CEO said turning cash flow positive soon
.
Okay. And then 1 last question for Scott. Do you have a breakeven sales number that you're working with?
Scott R. Burell - Chief Financial Officer, Principal Accounting Officer, Treasurer and Secretary
Yes. We're not providing forward-looking estimates at this time other than just what we've talked about before, which is this strategy of focusing on the prenatal markets and on the CMAs, those are the highest reimbursed tests that we perform. They carry the best gross margin of any of our tests, and that's where all of the growth is coming right now. So we're excited about maximizing that opportunity and I think in the relative short term, turning around that breakeven point relatively quickly. But that's probably about as much as we can comment at this time. L
END:NYSE $3.34 $6 per share EBITDA
END should be $15 at a MINIMUM. Annualized EBITDA of $250 Million.
END has a EBITDA run rate of $250 Million and more huge wells coming on production. At 6 x EBITDA this would be $15.
Insanely cheap.
STXS ($2.25) could move much higher after Tuesday earnings:
- 5 Million float
- Franklin Templeton owns 19%
-Rose to $3.50 in December after CEO said business is booming:
The company is seeing an acceleration in incoming orders which it believes will lead to "stronger financials in the future," said Stereotaxis' CEO Mike Kaminski. The response to Sterotaxis' new Vdrive, which enables surgeons to remotely manipulate catheters has been "exceptionally strong," the CEO said. The company estimates that 50% of its customers will upgrade to the new system this year and the product has triggered increased interest in buying new systems from Sterotaxis, Kaminski commented. Sterotaxis expects Vdrive to be launched in the U.S. in 2013, he added. Meanwhile, the company believes that it can expand to more geographic markets through additional partnerships, the CEO noted. In mid-morning trading, Stereotaxis jumped 70c, or 35%, to $2.70.
STXS ($2.25) could move much higher after Tuesday earnings:
- 5 Million float
- Franklin Templeton owns 19%
-Rose to $3.50 in December after CEO said business is booming:
The company is seeing an acceleration in incoming orders which it believes will lead to "stronger financials in the future," said Stereotaxis' CEO Mike Kaminski. The response to Sterotaxis' new Vdrive, which enables surgeons to remotely manipulate catheters has been "exceptionally strong," the CEO said. The company estimates that 50% of its customers will upgrade to the new system this year and the product has triggered increased interest in buying new systems from Sterotaxis, Kaminski commented. Sterotaxis expects Vdrive to be launched in the U.S. in 2013, he added. Meanwhile, the company believes that it can expand to more geographic markets through additional partnerships, the CEO noted. In mid-morning trading, Stereotaxis jumped 70c, or 35%, to $2.70.
I posted a few stock picks in this board.
I am not clear on the difference between a "shameless pump" and a "proper" stock post on a message board.
Is everyomne everyone who buys a stock and posts it on a message board a "shameless pumper"?
To be honest I think you are just a grumpy old fart!
SYNC trades at 4 x EBITDA, partnered with ZNGA
After the recent drop SINC is s screaming buy.
Back out $40 MM cash, valued at $50 MM or 4 x EBITDA
ZNGA and SYNC Partnership + Online Gaming = $10
.
Social game developer Zynga Inc. (ZNGA) recently signed a partnership deal with Synacor Inc. (SYNC), a cloud-based television services provider. Synacor’s cloud-based platform enables cable, satellite and telecom companies to deliver entertainment services and apps to their subscribers across multiple devices. The partnership will enable subscribers to directly access Zynga’s home page, games and in-game currency beginning 2013.
Social games, which are mostly free-to-play, primarily earn revenue from the sale of in-game currency that is used by players to purchase virtual items, power-ups and energy while playing. Zynga currency (also called credit) is used in most of its games namely Zynga Poker, Words With Friends, FarmVille2, ChefVille, CityVille, Bubble Safari and Ruby Blast.
Although the financial terms of the deal were not disclosed, such as revenue sharing of the in-game transactions between the two companies, we believe that the increasing usage of in-game currency will boost Zynga’s top-line growth going forward.
The partnership comes at an opportune time for Zynga. The company recently lost its exclusivity to Facebook (FB), which is a serious setback, considering the fact that the social networking platform has been its primary source of revenue over the last few years (currently 85.0% of Zynga”s traffic and 92.0% of its revenue). The Synacor deal will not only reduce Zynga’s dependence on the Facebook platform but will also expand its customer base going forward.
Synacor has a strong clientele of approximately 45 cable, satellite and telecom companies that include names such as Verizon and Charter. Its service reaches approximately 24 million households who have access to high-speed Internet. We believe that the partnership will allow Zynga to reach a sizable audience over the long term.
Lately, Zynga has been criticized for the lack of new and diversified gaming content, which is failing to attract new users. We believe that increasing penetration will attract new game developers, which will improve gaming content over the long term. We believe that the deal will also promote Zynga currency as a suitable alternative to Facebook Credit for many game developers, thereby boosting in-game transactional revenue going forward.
Over the last 12 months, Zynga has been entering into partnership deals in order to gain momentum in the social, free-to-play and casual gaming market. In October 2012, Zynga entered into a partnership deal with Gibraltar-based online gambling company bwin.party to offer real-money poker and casino-style games in the U.K.
In May, Zynga teamed up with American Express and created a new platform called Serve. In June 2012, the company announced a new network (Zynga with Friends) and also started providing programming tools to third party developers to publish online mobile games. Zynga also announced partnerships with Majesco Entertainment (COOL) and Atari.
However, we note that growth from these partnerships will take some time to materialize. In between, its games continue to lose popularity and money amid stiff competition from established players such as Electronic Arts (EA) and Activision Blizzard (ATVI). Further, the revised terms with Facebook (despite all Zynga initiatives to reduce exposure) will remain an overhang on the stock in the near term.
We remain Neutral on Zynga over the long term (6-12 months). Currently, Zynga has a Zacks #3 Rank, which implies a Hold rating in the short-term (1-3 months
Maybe "ouch" for anyone who bought at $3.68, but I bought at $2.96 average and sold most at $3.30 average.
Do you understand now?
Hope so, because I look for solid investment ideas on these boards, not petty remarks from simple minded types.
Got out of most of my DYNT at 3.30, a 10% gain. ouc.. er.. nice!